Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review

Table 9 Individual studies included for induction of clinical remission in Crohn’s disease

Study	Country	Intervention	Comparator	Study design	Follow-up	n	Induction of clinical remission
Thomsen et al[45]	Denmark, France, United Kingdom, Norway, Italy, Spain, Portugal, Greece, South Africa, Austria, Australia, and Ireland	Budesonide	Mesalamine	RCT	8 wk	182	69% (budesonide) 45% (mesalamine) (P = 0.001)1
		Budesonide	Mesalamine	RCT	16 wk	182	62% (budesonide) 36% (mesalamine) (P < 0.001)1
Pavez et al[41]	Chile	IFX	AZA	RCT	26 wk	508	0.44 (event rate IFX); 0.3 (event rate AZA)2

¹Clinical remission defined as Crohn’s Disease Activity Index (CDAI) ≤ 150;

²Clinical remission defined as CDAI less than 150 in patients who did not receive budesonide at a daily dose greater than 6 mg, or systemic corticosteroids for at least 3 wk. AZA: Azathioprine; IFX: Infliximab; n: Number of patients; RCT: Randomized clinical trial; CDAI: Crohn’s Disease Activity Index.